Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 5/20 | 0.55 |
| ▸ | CA2 | P00918 | 5/20 | 0.55 |
| ▸ | CA9 | Q16790 | 5/20 | 0.55 |
| ▸ | CA12 | O43570 | 4/20 | 0.55 |
| ▸ | CA7 | P43166 | 4/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | CFTR | P13569 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22481057 | 0.89 | LMNA (0.53) | LMNATSHRCA1CA2CA9 | |
| SCHEMBL15110844 | 0.86 | LMNA (0.58) | LMNATSHRCA1CA2CA9 | |
| SCHEMBL4408583 | 0.86 | CA12 (0.46) | LMNATSHRCA1CA2CA9 | |
| SCHEMBL28680548 | 0.85 | ALDH1A1 (0.53) | LMNATSHRCA1CA2CA9 | |
| SCHEMBL23925852 | 0.84 | CA12 (0.62) | TSHRCA1CA2CA9CA12 | |
| SCHEMBL17424944 | 0.84 | LMNA (0.59) | LMNATSHRCA1CA2CA9 | |
| SCHEMBL28059783 | 0.84 | CA12 (0.44) | LMNATSHRCA1CA2CA9 | |
| SCHEMBL28674480 | 0.82 | TSHR (0.53) | LMNATSHRCA1CA2CA9 | |
| SCHEMBL7870569 | 0.82 | ALDH1A1 (0.48) | LMNATSHRALDH1A1HSD17B10CFTR | |
| SCHEMBL26162755 | 0.82 | LMNA (0.47) | LMNATSHRCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368620-A1 | ARNT Degrading Compounds and Uses Thereof | CELGENE CORPORATION (US) | 2025-12-04 | — | — | US | disclosed |
| US-8076374-B2 | Used to treat diabetic and other glucagon related metabolic disorders such as obesity, hyperglycemia, atherosclerosis, ischemic heart disease, stroke, neuropathy, and wound healing; 3-{4-[1-Allyl-1-(4'-trifluoromethyl-biphenyl-4-yloxymethyl)-but-3-enyl]-benzoylamino}-propionic acid; | ELI LILLY AND COMPANY (US) | 2011-12-13 | — | — | US | disclosed |
| EP-1951659-B1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2010-07-14 | — | — | EP | disclosed |
| US-20080319074-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY | 2008-12-25 | — | — | US | disclosed |
| EP-1951659-A2 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | Eli Lilly & Company (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007114855-A2 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-10-11 | — | — | WO | disclosed |
| EP-0984009-A1 | Benzodioxincarboxylic acid hydrazides as insecticides | ROHM AND HAAS COMPANY (US) | 2000-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319074-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | GLP1R, GCGR, GIPR | LMNA 3722/4885TSHR 67/4885CA1 3814/4885 |
| US-20250368620-A1 | ARNT Degrading Compounds and Uses Thereof | ARNT, AHR, NR1H2 | LMNA 3378/4885TSHR 495/4885CA1 4707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.